Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MRTX save search
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Published: 2024-02-02 (Crawled : 14:30) - biospace.com/
RYZB | $62.49 0.03% 280K
|
|
| O: 0.03%
H: 0.11%
C: 0.0%
XYF | News | $3.8825 -0.45% -0.01% 340
|
Finance
|
| O: 1.04%
H: 1.79%
C: -1.23%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
financial results
Corcept Appoints Roberto Vieira as President, Oncology
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
CORT | News | $23.0 3.14% 3.04% 1.9M
|
Health Technology
|
| O: 0.6%
H: 2.48%
C: 2.48%
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Published: 2024-01-23 (Crawled : 14:30) - biospace.com/
MS | News 0 d | $93.76 1.81% -0.24% 5M
|
Finance
|
| O: -0.07%
H: 1.38%
C: 1.25%
EVR | $196.1 2.09% -0.01% 440K
|
Finance
|
| O: 0.35%
H: 0.29%
C: -0.26%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.22%
H: 1.49%
C: 0.89%
acquisition
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2024-01-10 (Crawled : 13:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.02%
H: 0.17%
C: -0.19%
krasg12 lung cancer cell treatment advanced
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
GNMSF | News | $290.34 0.23% 3.83% 340
|
Health Technology
|
| O: 6.62%
H: 2.29%
C: -0.06%
ZLAB | $15.12 0.87% 0.93% 430K
|
Health Technology
|
| O: 8.3%
H: 0.02%
C: -2.12%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: -0.57%
NVCR | $12.055 1.9% 1.87% 600K
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: -6.94%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.29%
H: 0.21%
C: -0.48%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.27%
H: 0.14%
C: -3.34%
GMAB | News | $28.56 -1.42% -1.51% 530K
|
Health Technology
|
| O: 7.35%
H: 0.44%
C: -2.18%
results
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-06 (Crawled : 15:00) - biospace.com/
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.75%
H: 0.59%
C: 0.27%
therapeutics financial results
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: -0.9%
H: 1.08%
C: 0.61%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.2%
H: 0.43%
C: -0.38%
KURA | News | $18.73 2.97% 2.93% 800K
|
Health Technology
|
| O: 0.13%
H: 6.0%
C: 5.25%
ko-2806 collaboration therapeutics agreement
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published: 2023-10-31 (Crawled : 06:00) - biospace.com/
MS | News 0 d | $93.76 1.81% -0.24% 5M
|
Finance
|
| O: 0.83%
H: 0.0%
C: 0.0%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.25%
H: 0.54%
C: 0.29%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | News | $3.8825 -0.45% -0.01% 340
|
Finance
|
| O: -3.19%
H: 4.87%
C: 4.87%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: -4.68%
H: 2.46%
C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.16%
H: 0.47%
C: 0.2%
financial results
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-17 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.04%
H: 0.35%
C: -0.53%
lung cancer cell results
Pancreatic Cancer Battle Boosted by $200M VC Firm
Published: 2023-09-19 (Crawled : 17:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.47%
H: 4.98%
C: 3.98%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.13%
H: 2.0%
C: 1.83%
MACK 4 | $14.73 0.0% 80K
|
Health Technology
|
| O: -0.41%
H: 0.9%
C: 0.74%
INCY | $51.65 -0.52% -0.58% 2.5M
|
Health Technology
|
| O: 0.03%
H: 2.18%
C: 1.8%
BNTX | News | $88.49 0.55% 0.59% 330K
|
Health Technology
|
| O: -0.01%
H: 1.99%
C: 1.28%
cancer pancreatic
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
Published: 2023-09-10 (Crawled : 04:20) - prnewswire.com
MS | News 0 d | $93.76 1.81% -0.24% 5M
|
Finance
| Email alert
Add to watchlist
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
lung conference world cancer response study
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-09-05 (Crawled : 20:00) - prnewswire.com
MS | News 0 d | $93.76 1.81% -0.24% 5M
|
Finance
|
| O: -1.87%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.36%
H: 0.86%
C: -1.17%
nasdaq grant therapeutics
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Published: 2023-08-29 (Crawled : 20:00) - prnewswire.com
MS | News 0 d | $93.76 1.81% -0.24% 5M
|
Finance
|
| O: 1.44%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.69%
H: 1.04%
C: 1.01%
conference global therapeutics
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.5%
H: 1.29%
C: -1.02%
lung conference world cancer results study
Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published: 2023-08-11 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Mirati Therapeutics Announces Pricing of Upsized Public Offering
Published: 2023-08-09 (Crawled : 05:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 23.42%
H: 8.46%
C: 6.87%
offering therapeutics
Mirati Therapeutics Announces Pricing of Upsized Public Offering - August 09, 2023
Published: 2023-08-09 (Crawled : 11:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 23.42%
H: 8.46%
C: 6.87%
offering therapeutics
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
Published: 2023-07-25 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: -2.19%
therapeutics report financial results
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
VLCN | $0.2946 26.38% 20.17% 15M
|
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
LRN 4 | $58.2 0.17% 7.56% 950K
|
Consumer Services
TOVX | News | $0.3769 -8.3% 7.46% 1.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.